image credit: Unsplash

Valneva’s chikungunya virus vaccine granted breakthrough designation

July 9, 2021


The chikungunya vaccine – VLA1553 – has also previously been awarded an FDA fast track designation and a European Medicines Agency (EMA) PRIME designation, in December 2018 and October 2020 respectively.

Chikungunya is a mosquito-borne viral disease caused by the chikungunya virus. Although the mortality with chikungunya virus is low, morbidity is high, with clinical symptoms including acute onset of fever, debilitating joint and muscle pain, headache, rash, nausea and chronic arthralgia.

Read More on Pharma Times